THERANOS

Elizabeth Holmes was 19 years old and a sophomore at Stanford when she dropped out in 2003 to start a company that would revolutionize blood testing. Her pitch was irresistible: instead of drawing vials of blood with needles, Theranos would run hundreds of diagnostic tests from a single drop of blood taken by a tiny finger prick.

Faster, cheaper, less painful. A device the size of a printer sitting in every pharmacy and home.

She filed her first patent while still at Stanford. She named the company "Real-Time Cures" before settling on Theranos — a mashup of "therapy" and "diagnosis." The pitch deck was Silicon Valley catnip: a young woman taking on the $75 billion blood testing industry, with a personal story about a family member who died from a condition that might have been caught with earlier testing.

The first investor was Tim Draper, a family friend and legendary VC. He put in $1 million.

The board she assembled read like a Washington power directory: Henry Kissinger, George Shultz, Sam Nunn, Jim Mattis. Not a single one had biotech experience.

That should have been the first red flag.

The idea was simple and genuinely good: miniaturize blood testing so it could be done from a finger prick instead of a needle draw, at a fraction of the cost. Theranos would license the technology to pharmacies — they signed a deal with Walgreens to put Theranos "wellness centers" in stores.

Revenue would come from test fees, insurance reimbursements, and eventually licensing the proprietary device (called the Edison, then the miniLab) to hospitals and clinics worldwide.

The problem? The Edison device never worked reliably.

Theranos secretly ran most of its tests on commercially available machines made by Siemens — the same ones every other lab used. When they did use their own device, results were wildly inaccurate.

They diluted finger-prick samples to have enough blood, which made results even less reliable. Patients received incorrect diagnoses.

Some were told they had conditions they didn't have. Others were told they were healthy when they weren't.

The Edison — Theranos's proprietary blood testing device. The size of a desktop printer, it was supposed to run 200+ diagnostic tests from a single finger prick.

It never reliably worked at scale. The miniLab — a second-generation device that was never commercially deployed.

Internal testing showed it failed to meet accuracy standards across most test categories. Theranos Wellness Centers — testing locations inside Walgreens stores in Arizona and California.

Patients came in for routine blood work. Many received inaccurate results.

Theranos grew through hype, not product. Holmes was a master storyteller.

She wore black turtlenecks like Steve Jobs. She lowered her voice to a baritone.

She put former secretaries of state on her board instead of scientists. Every piece of the performance was deliberate.

The Walgreens partnership in 2013 was the growth inflection point — a major pharmacy chain endorsing the technology gave it instant legitimacy. At peak hype, Theranos had 40 wellness centers in Arizona and was planning national expansion.

Media coverage was relentless and almost entirely uncritical. Forbes, Fortune, and Time all profiled Holmes as a visionary.

She graced magazine covers. She was named the youngest self-made female billionaire.

The problem was that nobody outside the company was allowed to independently verify the technology. Journalists wrote about the founder, not the science.

The biggest challenge was the one Theranos could never solve: making the technology actually work. From as early as 2006, internal scientists raised alarms that the Edison device couldn't produce accurate results.

Employees who questioned the technology were fired or threatened with lawsuits. NDAs were weaponized to keep everyone silent.

John Carreyrou, a Wall Street Journal reporter, published the first investigative piece in October 2015 based on tips from former employees. Theranos called it a smear campaign.

Holmes went on CNBC and declared the story was flat wrong. But the scrutiny had begun.

The FDA inspected and found massive problems. CMS (which regulates clinical labs) found the Theranos lab posed "immediate jeopardy to patient health and safety." Walgreens pulled out.

Investors sued. The SEC charged Holmes with fraud.

By 2018, the company was dissolved.

Theranos raised money almost exclusively from non-traditional tech investors — families, funds, and individuals with no biotech expertise. Tim Draper led the earliest investment.

The Walton family (Walmart heirs) invested $150 million. Rupert Murdoch put in $125 million.

The DeVos family invested $100 million. Partner Fund Management invested $96 million (and later sued).

None of the major Silicon Valley VC firms that specialize in biotech — Kleiner Perkins, Flagship, Third Rock — ever invested. That absence was telling.